Clinical trials: Retinitis
Retinal Degeneration, Retinitis Pigmentosa
Rod and Cone Mediated Function in Retinal Disease
Background: Retinal diseases cause the loss of rod and cone photoreceptors. Symptoms include vision loss and night blindness. Researchers want to learn about rod and cone function in healthy people and people with retinal…
- Conditions
- Retinal Degeneration, Retinitis Pigmentosa, Stargardt's Disease
- Trial name
- NCT02617966
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- National Eye Institute (NEI)
Usher Syndrome, Type 2A, Retinitis Pigmentosa 39
Rate of Progression in USH2A-related Retinal Degeneration
The overall goal of this project funded by the Foundation Fighting Blindness is to characterize the natural history of disease progression in patients with USH2A related retinal degeneration associated with congenital hearing…
- Trial name
- RUSH2A (NCT03146078)
- Where
- 14 sites in United States, Canada and 4 more
- Volunteers
- 127 people
- Sponsor
- Jaeb Center for Health Research
Retinitis Pigmentosa, Eye Diseases
Rate of Progression in EYS Related Retinal Degeneration
The overall goal of this project funded by the Foundation Fighting Blindness is to characterize the natural history of disease progression in patients with EYS mutations in order to accelerate the development of outcome measures…
- Trial name
- Pro-EYS (NCT04127006)
- Where
- 19 sites in United States, Canada and 5 more
- Volunteers
- 103 people
- Sponsor
- Jaeb Center for Health Research
Inherited Retinal Degeneration, Retinitis Pigmentosa
Universal Rare Gene Study: A Registry and Natural History Study of Retinal Dystrophies Associated With Rare Disease-Causing Genetic Variants
This is an international, multicenter study with two components: Registry A standardized genetic screening and a prospective, standardized, cross-sectional clinical data collection Enrollment is open to all genes on the RD Rare…
- Trial name
- Uni-Rare (NCT05589714)
- Where
- 36 sites in United States, Australia and 12 more
- Volunteers
- 1,500 people
- Sponsor
- Jaeb Center for Health Research
Rare Disorders, Undiagnosed Disorders
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research.
- Conditions
- Rare Disorders, Undiagnosed Disorders, Disorders of Unknown Prevalence, Cornelia De Lange Syndrome
- Trial name
- CoRDS (NCT01793168)
- Where
- United States
- Volunteers
- 20,000 people
- Sponsor
- Sanford Health
Retinitis Pigmentosa (RP), Inherited Retinal Diseases
Study to Evaluate the Efficacy of a Single Intravitreal Injection of RTx-015 in Participants With Retinitis Pigmentosa (PERCEPT)
The purpose of this clinical trial is to evaluate the effectiveness and safety of a single injection into the eye of an investigational gene therapy in participants with retinitis pigmentosa (RP).
- Trial name
- PERCEPT (NCT07901751)
- Testing
- RTx-015
- Where
- 14 sites in United States
- Volunteers
- 60 people
- Sponsor
- Ray Therapeutics, Inc.
Retinitis Pigmentosa (RP), Extensive Macular Atrophy With Pseudodrusen (EMAP)
Intravitreal Adalimumab in Inherited and Degenerative Retinal Diseases
This prospective, comparative pilot study investigates the safety and functional outcomes of intravitreal adalimumab (ADA) in patients with Retinitis Pigmentosa (RP) and Extensive Macular Atrophy with Pseudodrusen-like Appearance…
- Trial name
- ADARET (NCT07348588)
- Testing
- Intravitreal Adalimumab
- Where
- Brazil
- Volunteers
- 30 people
- Sponsor
- Centro de Pesquisa Rubens Siqueira
Low Vision, Retinitis Pigmentosa
Visual Performance Measures in a Virtual Reality Environment for Assessing Clinical Trial Outcomes in Those With Severely Reduced Vision
Purpose: To validate a newly developed battery of performance-based tests of visual function to be presented using virtual reality.
- Conditions
- Low Vision, Retinitis Pigmentosa, Stargardt Disease 1, Stargardt Disease 3
- Trial name
- NCT04281732
- Testing
- Virtual Reality Headset based tests
- Where
- United Kingdom
- Volunteers
- 18 people
- Sponsor
- Queen's University, Belfast
Eye Diseases, Retinitis Pigmentosa
Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Exosomes for NAION
This trial will study the safety and efficacy of intranasal delivery of cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cell exosomes for the treatment of non-arteritic ischemic optic neuropathy
- Conditions
- Eye Diseases, Retinitis Pigmentosa, Diabetic Retinopathy, Macular Degeneration
- Trial name
- NCT05147701
- Testing
- cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cell exosomes
- Where
- 2 sites in United States, Greece
- Volunteers
- 20 people
- Sponsor
- The Foundation for Orthopaedics and Regenerative Medicine
Retinitis Pigmentosa
Safety and Tolerability Study of Gene Editing Drug ZVS203e in Participants With Retinitis Pigmentosa
The purpose of this study is to evaluate the safety, tolerability and efficacy of a single escalating doses of ZVS203e administered via subretinal injection in participants with RP caused by RHO site-specific gene mutation…
- Trial name
- NCT05805007
- Testing
- ZVS203e
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Peking University Third Hospital
Primary Photoreceptor Disease, Retinitis Pigmentosa (RP)
A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO)
Study OpCT-001-101 is a Phase 1/2a first-in-human, multisite, 2-part interventional study to evaluate the safety, tolerability, and the effect on clinical outcomes of OpCT-001 in approximately 54 adults with primary photoreceptor…
- Conditions
- Primary Photoreceptor Disease, Retinitis Pigmentosa (RP), Usher Syndrome, Inherited Retinal Disease (IRD)
- Trial name
- CLARICO (NCT06789445)
- Testing
- OpCT-001
- Where
- 5 sites in United States
- Volunteers
- 54 people
- Sponsor
- BlueRock Therapeutics
Retinitis Pigmentosa (RP), Usher Syndrome
A 24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome
The goal of this clinical trial is to learn if NPI-001 works to prevent progression of retinitis pigmentosa in adults diagnosed with Usher syndrome. It will also provide information about the safety of NPI-001.
- Trial name
- SLORP Preserve (NCT07710196)
- Testing
- NPI-001
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Nacuity Pharmaceuticals, Inc.
Retinal Light Damage, Photic Retinopathy
OCTA Evaluated the Efficacy of Glucocorticoid Retrobulbar Injection in Retinal Photo-injury
The goal of this retrospective observational study is to evaluate the effectiveness of retrobulbar glucocorticoid injection in patients with retinal photo-injury.
- Conditions
- Retinal Light Damage, Photic Retinopathy, Photic Maculopathy
- Trial name
- NCT07869511
- Testing
- retrobulbar injection of glucocorticoid
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Rod Cone Dystrophy
Natural History Study of Advanced RCD
ECSTASI is a Natural History Study, which will be monitoring how standard of care (SoC) affect advanced rod-cone dystrophy (RCD), a type of eye disease also known as retinitis pigmentosa.
- Trial name
- ECSTASI (NCT07854899)
- Testing
- Eye examinations, Questionnaire
- Where
- 3 sites in Belgium, France and 1 more
- Volunteers
- 100 people
- Sponsor
- SparingVision
Retinitis Pigmentosa (RP)
Safety Evaluation Study of Pitavastatin PLGA Nano-particle for Retinitis Pigmentosa
Retinitis pigmentosa (RP) is a rare inherited retinal degenerative disease that causes progressive visual field loss and vision impairment, often leading to blindness.
- Trial name
- RP CLARITI (NCT07774975)
- Testing
- ULREA-PVS-NP
- Where
- Japan
- Volunteers
- 21 people
- Sponsor
- Kyushu University
MelanomaCutaneous Melanoma Resectable, Melanoma
Neoadjuvant RP2 + Nivolumab in Patients With Melanoma
This is a Phase II study is being done to determine whether a new combination of therapies is safe and effective for adults to treat Melanoma before surgery.
- Trial name
- NCT07862530
- Testing
- RP2 (vusolimogene oderparepvec), Nivolumab, Definitive Surgical Resection
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Yana Najjar
Retinitis Pigmentosa
Expanded Access Program for RP in Adults
This intermediate-size patient population expanded access program is to provide access to investigational product OCU400 for up to 75 patients with Retinitis Pigmentosa (RP) outside of the ongoing clinical trial Phase 3 program…
- Trial name
- NCT06574997
- Testing
- OCU400
- Where
- 5 sites in United States
- Sponsor
- Ocugen
Retinitis Pigmentosa (RP)
Phase I/II Open-Label Trial of UGX202 for Advanced Retinitis Pigmentosa
This is a single-arm, open-label study employing a 3+3 dose escalation design to evaluate two UGX202 dose groups: the low-dose group (1.2×10¹¹ vg/eye) and the high-dose group (3.5×10¹¹ vg/eye).
- Trial name
- UGX202 (NCT07847723)
- Testing
- UGX202 Injection
- Volunteers
- 12 people
- Sponsor
- Suzhou UgeneX Therapeutics Co., Ltd.
X-Linked Retinitis Pigmentosa
Long-term Follow-up Gene Therapy Study for RPGR- XLRP
This is a long-term follow-up study assessing safety of patients for up to 60 months following advanced therapy investigational medicinal product (ATIMP) AAV5-hRKp.RPGR vector in participants with XLRP caused by mutations in RPGR.
- Trial name
- NCT04312672
- Testing
- AAV5-hRKp.RPGR
- Where
- 5 sites in United States, United Kingdom
- Volunteers
- 42 people
- Sponsor
- MeiraGTx Ocular UK Ltd
X-Linked Retinitis Pigmentosa
Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene
A clinical trial of AAV5-hRKp.RPGR vector for participants with X-linked retinitis pigmentosa (XLRP)
- Trial name
- NCT04794101
- Testing
- Genetic: AAV5-hRKp.RPGR Intermediate Dose, Genetic: AAV5-hRKp.RPGR Low Dose
- Where
- 28 sites in United States, Belgium and 9 more
- Volunteers
- 97 people
- Sponsor
- MeiraGTx Ocular UK Ltd